目的:了解2021年重庆市宫颈癌发病率、死亡率与五年生存率,为开展恶性肿瘤防治提供依据。方法:收集整理2021年重庆市新发宫颈癌发病死亡数据,分析2021年重庆市宫颈癌发病率、标化发病率、死亡率、标化死亡率、年龄别发病率与死亡率。中...目的:了解2021年重庆市宫颈癌发病率、死亡率与五年生存率,为开展恶性肿瘤防治提供依据。方法:收集整理2021年重庆市新发宫颈癌发病死亡数据,分析2021年重庆市宫颈癌发病率、标化发病率、死亡率、标化死亡率、年龄别发病率与死亡率。中国人口标化率采用2000年第五次人口普查标准人口构成进行标化,世界人口标化率采用2000年世界人口构成进行标化。不同性别和地区率的比较采用χ^(2)检验。对2016年新报告的宫颈癌病例进行主动和被动生存随访,采用生存分析寿命表法计算观察生存率,采用乘积极限法(Kaplan-Meier)计算平均生存时间,生存率的比较采用Log Rank of Mantel-Cox进行统计检验。结果:2021年重庆市宫颈癌发病率、中国标化发病率、世界标化发病率分别为21.60/10万、14.64/10万与14.71/10万,宫颈癌发病率农村(23.32/10万)高于城市(17.67/10万)(χ^(2)=6.96,P<0.01)。宫颈癌死亡率、中国标化死亡率、世界标化死亡率分别为5.00/10万、2.79/10万与3.02/10万,宫颈癌死亡率农村(5.65/10万)高于城市(3.53/10万)(χ^(2)=5.42,P=0.02)。2021年重庆市宫颈癌五年生存率为64.32%,城市地区宫颈癌五年生存率(76.35%)高于农村地区(59.79%),差异有统计学意义(χ^(2)=46.65,P<0.01)。结论:重庆市宫颈癌发病率与死亡率高,五年生存率较低,应重视宫颈癌的防治。展开更多
Breast cancer,a predominant global health issue,requires ongoing exploration of new therapeutic strategies.Palbociclib(PAL),a well-known cyclin-dependent kinase(CDK)inhibitor,plays a critical role in breast cancer tre...Breast cancer,a predominant global health issue,requires ongoing exploration of new therapeutic strategies.Palbociclib(PAL),a well-known cyclin-dependent kinase(CDK)inhibitor,plays a critical role in breast cancer treatment.While its efficacy is recognized,the interplay between PAL and cellular autophagy,particularly in the context of the RAF/MEK/ERK signaling pathway,remains insufficiently explored.This study investigates PAL’s inhibitory effects on breast cancer using both in vitro(MCF7 and MDA-MB-468 cells)and in vivo(tumor-bearing nude mice)models.Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib(TRA),an MEK inhibitor,our research seeks to address the challenge of PAL-induced drug resistance.Ourfindings reveal that PAL significantly decreases the viability of MCF7 and MDA-MB-468 cells and reduces tumor size in mice while showing minimal cytotoxicity in MCF10A cells.However,PAL also induces protective autophagy,potentially leading to drug resistance via the RAF/MEK/ERK pathway activation.Introducing TRA effectively neutralized this autophagy,enhancing PAL’s anti-tumor efficacy.A combination of PAL and TRA synergistically reduced cell viability and proliferation,and in vivo studies showed notable tumor size reduction.In conclusion,the PAL and TRA combination emerges as a promising strategy for overcoming PAL-induced resistance,offering a new horizon in breast cancer treatment.展开更多
文摘目的:了解2021年重庆市宫颈癌发病率、死亡率与五年生存率,为开展恶性肿瘤防治提供依据。方法:收集整理2021年重庆市新发宫颈癌发病死亡数据,分析2021年重庆市宫颈癌发病率、标化发病率、死亡率、标化死亡率、年龄别发病率与死亡率。中国人口标化率采用2000年第五次人口普查标准人口构成进行标化,世界人口标化率采用2000年世界人口构成进行标化。不同性别和地区率的比较采用χ^(2)检验。对2016年新报告的宫颈癌病例进行主动和被动生存随访,采用生存分析寿命表法计算观察生存率,采用乘积极限法(Kaplan-Meier)计算平均生存时间,生存率的比较采用Log Rank of Mantel-Cox进行统计检验。结果:2021年重庆市宫颈癌发病率、中国标化发病率、世界标化发病率分别为21.60/10万、14.64/10万与14.71/10万,宫颈癌发病率农村(23.32/10万)高于城市(17.67/10万)(χ^(2)=6.96,P<0.01)。宫颈癌死亡率、中国标化死亡率、世界标化死亡率分别为5.00/10万、2.79/10万与3.02/10万,宫颈癌死亡率农村(5.65/10万)高于城市(3.53/10万)(χ^(2)=5.42,P=0.02)。2021年重庆市宫颈癌五年生存率为64.32%,城市地区宫颈癌五年生存率(76.35%)高于农村地区(59.79%),差异有统计学意义(χ^(2)=46.65,P<0.01)。结论:重庆市宫颈癌发病率与死亡率高,五年生存率较低,应重视宫颈癌的防治。
基金The National Science Foundation of China (No.52078190)the Natural Science Foundation of Jiangsu Province (No.BK20221501)+1 种基金the Natural Science Youth Fund of Jiangsu Province(No.BK20220983)the Natural Science Foundation of Hebei Province(No.E2019203559)。
基金supported by the Sichuan Science and Technology Program(Grant Nos.2020YJ0494,24GJHZ0058,21RCYJ0021,and 2022YFS0620)the National Natural Science Foundation of China(Grant No.81903829)+1 种基金the Southwest Medical University Science and Technology Program(Grant Nos.2021ZKZD015,2021ZKZD018,and 2021ZKMS046)the Macao Science and Technology Development Fund of Macao SAR(Project Nos.SKLQRCM(MUST)-2020-2022 and MUST-SKL-2021-005).
文摘Breast cancer,a predominant global health issue,requires ongoing exploration of new therapeutic strategies.Palbociclib(PAL),a well-known cyclin-dependent kinase(CDK)inhibitor,plays a critical role in breast cancer treatment.While its efficacy is recognized,the interplay between PAL and cellular autophagy,particularly in the context of the RAF/MEK/ERK signaling pathway,remains insufficiently explored.This study investigates PAL’s inhibitory effects on breast cancer using both in vitro(MCF7 and MDA-MB-468 cells)and in vivo(tumor-bearing nude mice)models.Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib(TRA),an MEK inhibitor,our research seeks to address the challenge of PAL-induced drug resistance.Ourfindings reveal that PAL significantly decreases the viability of MCF7 and MDA-MB-468 cells and reduces tumor size in mice while showing minimal cytotoxicity in MCF10A cells.However,PAL also induces protective autophagy,potentially leading to drug resistance via the RAF/MEK/ERK pathway activation.Introducing TRA effectively neutralized this autophagy,enhancing PAL’s anti-tumor efficacy.A combination of PAL and TRA synergistically reduced cell viability and proliferation,and in vivo studies showed notable tumor size reduction.In conclusion,the PAL and TRA combination emerges as a promising strategy for overcoming PAL-induced resistance,offering a new horizon in breast cancer treatment.
